Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Dyne Therapeutics Inc DYN

Healthcare Biotechnology
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:DYN)

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

GlobeNewswire 3 days ago

Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 8 days ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

GlobeNewswire 11 days ago

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

GlobeNewswire January 20, 2026

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2026

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

GlobeNewswire December 23, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire December 11, 2025

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

GlobeNewswire December 9, 2025

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire December 8, 2025
View More News ››

Opinion & Analysis (NDAQ:DYN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DYN)

Buy buddy buy.

Otherwise it will be FOMO time for you fellas out there today anyway,so good luck to all
coolfooldumbguy - October 27, 2025
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc., an oil and natural gas company, engages in the acquisition, development, exploration, and production ...
View More »

Podcasts